Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results

KRYSTEXXA: MIRROR RCT Underway to Potentially Expand Prescribing Information Immunomodulation has potential to significantly increase KRYSTEXXA response rate Increase physician MIRROR Randomized Clinical Trial Design 135 Patients Evaluated for 24 Weeks KRYSTEXXA + methotrexate (n=90) 12 infusions: 1 every two weeks confidence Allow patients to stay on therapy longer . Following MIRROR RCT readout, potential to expand prescribing information RCT: Randomized controlled trial. HI HORIZON KRYSTEXXA + placebo (n=45) 12 infusions: 1 every two weeks Day 1 Initiated Q2 2019; Data Readout Expected in 2021 Week 24 Primary Endpoint Primary Endpoint at Week 24: Proportion of serum uric acid (SUA) responders (sUA <6 mg/dL) at Month 6 29

View entire presentation